Neurizon Therapeutics Ltd (NUZTF) Financiero

Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-10-05. The firm is engaged in advancing treatments for neurodegenerative diseases. The firm is focused on developing its lead drug candidate, NUZ-001, for the treatment of Amyotrophic Lateral Sclerosis (ALS), which is the common form of motor neuron disease. ALS is a devastating neurodegenerative condition that primarily affects nerve cells that control voluntary muscles.